Metropolis Healthcare reported 30% fall in consolidated net profit to Rs 41.2 crore despite a 7% rise in total revenue from operations to Rs 293.1 crore in Q3 FY22 over Q3 FY21.
Reported EBIDTA in Q3 FY22 was Rs 76.2 crore, down by 12% from Rs 86.7 crore in Q3 FY21. Reported EBIDTA Margin was 26% in Q3 FY22 as against 31.5% in Q3 FY21.
Ameera Shah, promoter and managing director, Metropolis Healthcare said: During Q3FY22, we are pleased to share that we have been able to grow our non-covid revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital& marketing, manpower& customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short term phenomenon.
Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.
We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.
The company said its board has declared an interim dividend of Rs 8 per share for the financial year 2021-22.
Metropolis Healthcare is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities.
The scrip fell 1.63% to Rs 2419.95 on the BSE.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU